PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients

Background: Bevacizumab-based regimens are used as standard treatments for colorectal cancer. Unfortunately, there are no established predictive markers for bevacizumab response. Methods: Tumor samples from 36 metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy were anal...

Full description

Bibliographic Details
Main Authors: Hung-Chih Hsu, Nina Lapke, Shu-Jen Chen, Yen-Jung Lu, Ren-Shiang Jhou, Chien-Yuh Yeh, Wen-Sy Tsai, Hsin-Yuan Hung, Jason Chia-Hsun Hsieh, Tsai-Sheng Yang, Tan Kien Thiam, Jeng-Fu You
Format: Article
Language:English
Published: MDPI AG 2018-09-01
Series:Cancers
Subjects:
metastatic colorectal cancer
bevacizumab resistance
next-generation sequencing
VEGF
PTPRT/PTPRD mutation and deletion
Online Access:http://www.mdpi.com/2072-6694/10/9/314

Internet

http://www.mdpi.com/2072-6694/10/9/314

Similar Items